SAN CARLOS

Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

Retrieved on: 
火曜日, 5月 28, 2024
Patient, Immunoglobulin E, Pharmacokinetics, UAS7, CSU, Skin, Safety, B cell, SAN, Pharmaceutical industry

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and to explore the therapeutic effects of AK006 in patients with CSU using the urticaria activity score (UAS7) at 14 weeks. Top-line results from the trial are expected at year end 2024.

Key Points: 
  • SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006.
  • The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and to explore the therapeutic effects of AK006 in patients with CSU using the urticaria activity score (UAS7) at 14 weeks.
  • Top-line results from the trial are expected at year end 2024.
  • IgE-dependent mast cell activation has been identified as a pathogenic driver of CSU, and agents which target this pathway have demonstrated therapeutic activity.

Iovance Biotherapeutics to Present at Upcoming Conferences and Events

Retrieved on: 
金曜日, 5月 24, 2024
Iovance Biotherapeutics, Patient, EHA, Cancer, TIL, SAN, ASCO

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events:

Key Points: 
  • SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events:
    TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA
    Presentation and Key Opinion Leader Panel Discussion: May 31, 2024 at 7:15 p.m.
  • ET

Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
IOV, Interleukin, McCormick Place, ICI, Patient, TIL, Pembrolizumab, Cohort, Food, Clinical trial, CDT, FDA, EDT, Disease, Safety, SAN, RECIST, Cancer, Melanoma, ASCO, Webcast, Pharmaceutical industry

SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online.

Key Points: 
  • Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy.
  • Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1.
  • TILVANCE-301 is a global, randomized, registrational Phase 3 trial to support accelerated and full U.S. approvals of lifileucel in combination with pembrolizumab in frontline advanced melanoma.
  • The live and archived webcast can be accessed in the Investors section of the Company’s website, IR.Iovance.com for one year.

Presto Automation Announces Fiscal Third Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 21, 2024
Human voice, Restaurant, Machine learning, SAN, Form, Growth, Interim, GAAP, Somatosensory system, Adjustment, Webcast, Sales

SAN CARLOS, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- -- Presto Automation Inc. (NASDAQ: PRST), one of the largest drive-thru AI and automation technology providers to the restaurant industry, today announced financial results for the 2024 fiscal third quarter ended March 31, 2024.

Key Points: 
  • SAN CARLOS, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- -- Presto Automation Inc. (NASDAQ: PRST ), one of the largest drive-thru AI and automation technology providers to the restaurant industry, today announced financial results for the 2024 fiscal third quarter ended March 31, 2024.
  • Presto will exit this business line with the expiration of its final customer contracts at the end of June 2024.
  • Presto took decisive action to focus exclusively on its leading Presto Voice AI solution for drive-thru operators by winding down the Touch pay-at-table solution.
  • Presto expects total revenue for the fiscal fourth quarter of 2024 to be in the range of $1.6 million to $1.9 million.

Presto Announces Pilot of Spanish Voice AI for Drive-Thrus

Retrieved on: 
月曜日, 5月 20, 2024
Restaurant, SAN, Language, Customer service

SAN CARLOS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Presto Automation Inc. (“Presto” or the “Company”) (NASDAQ: PRST), one of the largest AI and automation technology providers to the restaurant industry, today announced the pilot program of its Presto Voice™ Spanish Voice AI ordering feature.

Key Points: 
  • SAN CARLOS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Presto Automation Inc. (“Presto” or the “Company”) (NASDAQ: PRST), one of the largest AI and automation technology providers to the restaurant industry, today announced the pilot program of its Presto Voice™ Spanish Voice AI ordering feature.
  • Presto Voice’s new AI feature will allow drive-thru customers to easily place orders in Spanish with the ability to effortlessly transition between English and Spanish when necessary.
  • “We understand the importance of providing a seamless and inclusive experience for all restaurant guests and are excited to enhance Presto Voice’s capabilities to address this important demographic,” said Gee Lefevre, interim CEO of Presto.
  • “This development will not only enable Presto to serve more customers in the U.S. but also opens up possibilities to expand internationally.

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
金曜日, 5月 17, 2024
Patient, Cancer, Employment, SAN, Date

SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 16, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance’s common stock to thirty new, non-executive employees.

Key Points: 
  • SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 16, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance’s common stock to thirty new, non-executive employees.
  • The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13, 2023, and February 26, 2024 and provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each of the stock options granted as referenced in this press release has an exercise price of $10.43, the closing price of Iovance’s common stock on the Date of Grant.
  • Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

Presto to Report Fiscal Third Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 14, 2024
Presto, SAN

SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Presto Automation Inc. (NASDAQ: PRST ), one of the largest drive-thru AI and automation technology providers to the restaurant industry, today announced that the Company will release its fiscal third quarter 2024 financial results on Monday, May 20, 2024, after the financial markets close.

Key Points: 
  • SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Presto Automation Inc. (NASDAQ: PRST ), one of the largest drive-thru AI and automation technology providers to the restaurant industry, today announced that the Company will release its fiscal third quarter 2024 financial results on Monday, May 20, 2024, after the financial markets close.
  • Presto management will host a conference call at 5:00 p.m. Eastern Time on Wednesday, May 22, 2024, to discuss the financial results and other business highlights.

Oportun Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
Rate, ROE, Earnings per share, EPS, End, GAAP

Originations – Aggregate Originations for the first quarter were $338 million, a decrease of 17% as compared to $408 million in the prior-year quarter.

Key Points: 
  • Originations – Aggregate Originations for the first quarter were $338 million, a decrease of 17% as compared to $408 million in the prior-year quarter.
  • Revenue – Total revenue for the first quarter was $250 million, a decrease of 3% as compared to $260 million in the prior-year quarter.
  • Net Charge-Off Rate – The Annualized Net Charge-Off Rate for the quarter was 12.0%, compared to 12.1% for the prior-year quarter.
  • Oportun is providing the following guidance for 2Q 2024 and full year 2024 as follows:

Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Retrieved on: 
木曜日, 5月 9, 2024
Momentum, IOV, Epidemiology, FDA, Investment, Lung cancer, Intellectual property, Research, National Cancer Institute, Units of paper quantity, ASCO, Endometrial cancer, TIL, Death, Cancer, Food, Second generation, Food and Drug Administration, Safety, Poster, Uterine cancer, PD-1, Next Generation, Melanoma, Marketing, Clinical trial, Investigational New Drug, Cohort, MMR, Information, Patient, Society, Interim, Growth, Pharmaceutical industry

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates. 

Key Points: 
  • Launch Following U.S. Food and Drug Administration (FDA) Approval
    SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2024 financial results and corporate updates.
  • Iovance remains on track to onboard approximately 50 ATCs by the end of May 2024 and expects to have more than 70 ATCs onboarded by the end of 2024.
  • In the first quarter of 2024, Iovance completed the transfer of marketing authorizations and began distribution of Proleukin.
  • Beginning in the second quarter of 2024, Iovance expects to recognize significant incremental revenues for Proleukin as part of the Amtagvi treatment regimen.

Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
AAAAI, American Academy, Inflammation, Investment, Pharmacokinetics, Research, SAD, Lirentelimab, Patient, Allergy, Antibody, Annual general meeting, PD, CSU, SAN, Pharmaceutical industry

SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  • Allakos’ financial outlook, restructuring activities and estimated cash runway as reported by the Company in January 2024 remain unchanged.
  • Allakos reported a net loss of $71.1 million in the first quarter of 2024 compared to $42.4 million in the first quarter of 2023.
  • Net loss per basic and diluted share was $0.81 for the first quarter of 2024 compared to $0.49 in the first quarter of 2023.